Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Science, medicine, and the future: Pharmacogenetics.

Literature DB >> 10753155

Science, medicine, and the future: Pharmacogenetics.

C R Wolf¹, G Smith, R L Smith.

Abstract

Mesh：

Year: 2000 PMID： 10753155 PMCID： PMC1117913 DOI： 10.1136/bmj.320.7240.987

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

9 in total

Review 1. Pharmacogenetics.

Authors: C R Wolf; G Smith
Journal: Br Med Bull Date: 1999 Impact factor: 4.291

2. The cost of adverse drug reactions.

Authors: J P Griffin
Journal: Adverse Drug React Toxicol Rev Date: 1997-06

3. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

Authors: J Lazarou; B H Pomeranz; P N Corey
Journal: JAMA Date: 1998-04-15 Impact factor: 56.272

4. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Authors: W H Chou; F X Yan; J de Leon; J Barnhill; T Rogers; M Cronin; M Pho; V Xiao; T B Ryder; W W Liu; C Teiling; P J Wedlund
Journal: J Clin Psychopharmacol Date: 2000-04 Impact factor: 3.153

Review 5. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

Authors: E Y Krynetski; H L Tai; C R Yates; M Y Fessing; T Loennechen; J D Schuetz; M V Relling; W E Evans
Journal: Pharmacogenetics Date: 1996-08

6. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

Authors: L Bertilsson; M L Dahl; F Sjöqvist; A Aberg-Wistedt; M Humble; I Johansson; E Lundqvist; M Ingelman-Sundberg
Journal: Lancet Date: 1993-01-02 Impact factor: 79.321

7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

Authors: G P Aithal; C P Day; P J Kesteven; A K Daly
Journal: Lancet Date: 1999-02-27 Impact factor: 79.321

8. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

Authors: L Lennard; J S Lilleyman; J Van Loon; R M Weinshilboum
Journal: Lancet Date: 1990-07-28 Impact factor: 79.321

9. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

Authors: I Johansson; E Lundqvist; L Bertilsson; M L Dahl; F Sjöqvist; M Ingelman-Sundberg
Journal: Proc Natl Acad Sci U S A Date: 1993-12-15 Impact factor: 11.205

9 in total

41 in total

Review 9. [Pharmacogenetics].

Authors: H F Merk
Journal: Hautarzt Date: 2010-08 Impact factor: 0.751

Review 10. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.

Authors: Katherine I Morley; Wayne D Hall
Journal: J Mol Med (Berl) Date: 2003-11-04 Impact factor: 4.599

Science, medicine, and the future: Pharmacogenetics.

Review 1. Pharmacogenetics.

2. The cost of adverse drug reactions.

3. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

4. Extension of a pilot study: impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness.

Review 5. Genetic polymorphism of thiopurine S-methyltransferase: clinical importance and molecular mechanisms.

6. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

7. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

8. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia.

9. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

Review 1. The challenge of integrating genetic medicine into primary care.

2. Pharmacogenetics and pharmacogenomics.

Review 3. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs.

4. Use of polymorphism analysis required ethical guidelines.

Review 5. Ethical reflections on pharmacogenetics and DNA banking in a cohort of HIV-infected patients.

6. Metoclopramide in the treatment of diabetic gastroparesis.

Review 7. Medical genetics: 1. Clinical teratology in the age of genomics.

Review 8. Host-environment medicine: a primary care model for the age of genomics.

Review 9. [Pharmacogenetics].

Review 10. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.